Where others have failed will Atl1102 succeed ?, page-552

2 ASX biotech shares that could be the next CSL

Share price cracked through the $300 per share barrier to start the year and is well poised to become the most valuable listed company on the ASX.Boosted by acquisitions and strong organic growth of 8.8%, Q1 revenues climbed 27.2% from the prior year to $984.7 million. Sales from its CCM segment were up 34.2% to $598.6 million on continued healthy demand in its commercial construction business and $120.0 million in contributions from [Shareprice $287.00Market cap $132.35 billion————————-

Mesoblast Limited (ASX: MSB)

Mesoblast
is a world leader in developing off-the-shelf (allogeneic) regenerative medicines for inflammatory diseases. The company has used its cell therapy technology to establish a broad portfolio of commercial products and has a large pipeline of therapies in late stage development and testing.The $3 billion biotech revealed revenues of $US32.2 million ($44.5 million) for 2020, a 92 per cent improvement on 2019's numbers. This was largely driven by royalty and milestone payments to the company from its strategic partnerships with other biotechs.Shareprice $1.52market cap $999 million————————-

Medical Developments International Ltd (ASX: MVP)

Medical Developments is an Australian company that specialises in products that address emergency pain relief and respiratory problems. The company’s products are used in emergency departments and other medical settings including the Australian Defence Force and Australian Ambulance Service.

Revenue increased 12.1% on the prior corresponding period (pcp) to $25.6 million and gross profit leaped 27.4% to $19.1 million.Share price $4.95Market cap : $368 mill
———-
ITSA-
I
don’t think we can beat CSLBut like I said in my previous post some 3 weeks ago… Anp can be the Second largest Australian Biotech..$$$$$